Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;36(4):387-392.
doi: 10.23876/j.krcp.2017.36.4.387. Epub 2017 Dec 31.

Acute kidney injury aggravated by treatment initiation with apixaban: Another twist of anticoagulant-related nephropathy

Affiliations

Acute kidney injury aggravated by treatment initiation with apixaban: Another twist of anticoagulant-related nephropathy

Sergey V Brodsky et al. Kidney Res Clin Pract. 2017 Dec.

Abstract

Anticoagulant-related nephropathy (ARN) was initially described in patients on warfarin (as warfarin-related nephropathy) and recently in those using dabigatran. Herein, we report clinical history and kidney biopsy findings in a patient on apixaban (Eliquis). Initiation of treatment with apixaban resulted in aggravation of preexisting mild acute kidney injury (AKI). A few days after apixaban therapy, the patient became oligoanuric, and kidney biopsy showed severe acute tubular necrosis with numerous occlusive red blood cell casts. Only one out of 68 glomeruli with open capillary loops had small segmental cellular crescent. Therefore, there was major discrepancy between the degree of glomerular injury and the glomerular hematuria. Considering that the onset of this AKI was associated with apixaban treatment initiation, we propose that this patient had ARN associated with factor Xa inhibitor (apixaban), which has not previously been described. Monitoring of kidney function is recommended after initiation of anticoagulant therapy.

Keywords: Acute kidney injury; Anticoagulant-related nephropathy; Kidney biopsy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest All authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1. Serum creatinine changes in association with apixaban treatment
Changes in serum creatinine level are shown by a solid line. Initiation of treatment with apixaban and kidney biopsy time are depicted by arrows. Hematuria prior and after apixaban therapy is shown as urinalysis (UA). Specific dates are depicted on the X axis, and the corresponding serum creatinine levels are shown above. HPF, high power field; RBC, red blood cell.
Figure 2
Figure 2. Light microscopy kidney biopsy findings (H&E stain)
(A) A single small segmental cellular crescent is noted in one out of 68 glomeruli with open capillary loops (×100). (B) Numerous occlusive red blood cell casts were seen in the tubules. Acute tubular necrosis is present (×100). (C) Red blood cells were filling Bowman’s space in some glomeruli (×200).
Figure 3
Figure 3. Immunofluorescence and electron microscopy findings
(A) Trace segmental granular staining in the mesangium was seen by direct immunofluorescence with an antibody to immunoglobulin A (fluorescein isothiocyanate [FITC], ×400). (B) Mild granular staining in the mesangium was seen by direct immunofluorescence with an antibody to C3 (FITC, ×400). (C) Occasional small electron dense deposits were seen in the mesangium by ultrastructural examination (×5,000). (D) Dysmorphic red blood cells in Bowman’s space were seen by electron microscopy. Of note, no deposits were seen in the glomerular basement membrane of the mesangium in this segment of the glomerulus (×4,000).

References

    1. Brodsky SV, Collins M, Park E, et al. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract. 2010;115:c142–c146. doi: 10.1159/000312877. - DOI - PMC - PubMed
    1. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011;80:181–189. doi: 10.1038/ki.2011.44. - DOI - PMC - PubMed
    1. Brodsky SV, Satoskar A, Chen J, et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis. 2009;54:1121–1126. doi: 10.1053/j.ajkd.2009.04.024. - DOI - PubMed
    1. Kadiyala D, Brewster UC, Moeckel GW. Dabigatran induced acute kidney injury. Proceedings of The American Society of Nephrology annual meeting; November 1–4, 2012; San Diego. San Diego: The American Society of Nephrology; 2012. FR-PO1122.
    1. Berger R, Salhanick SD, Chase M, Ganetsky M. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin. Ann Emerg Med. 2013;61:475–479. doi: 10.1016/j.annemergmed.2013.02.008. - DOI - PubMed

LinkOut - more resources